A large clinical trial evaluating high dose biotin (MD1003, Qizenday) in secondary and primary progressive MS has failed to show that the treatment leads to improvements in disability.
Topline results from the study have been announced in a press release from the manufacturer, MedDay. Detailed results of the study will be presented at the American Academy of Neurology (AAN) meeting in Toronto, April 2020.
About the study
The SPI2 trial evaluated the safety and effectiveness of three daily doses of 100mg of high dose biotin compared to placebo in 642 people with progressive MS without recent relapses, also called non-active progressive MS. The main measure of the study was an improvement in disability, which could be either a lower EDSS score or a reduction in the time to walk 25 feet. There was no improvement in either of these measures in comparison to the placebo group.
MD1003 is a highly concentrated formulation of biotin which has been undergoing clinical studies.
An earlier clinical trial (MS-SPI) which recruited 154 participants with progressive MS had provided initial evidence that high doses of biotin might have an impact on disability and progression. The main measure of the study was improvement in disability after 9 months of treatment which was still evident at 12 months. Improvement in disability could be either a reduction in EDSS or a reduction in the time to walk 25 feet. Slightly less than 13% of the MD1003 group and none of the placebo group met this criteria.
Biotin, also known as vitamin H or coenzyme R, is one of the B-group vitamins (vitamin B7). It is involved in a wide range of cell processes. It has been suggested that very high doses of biotin may be effective in MS by promoting myelin repair through activation of an enzyme involved in myelin synthesis and by enhancing energy production in demyelinated nerves.
Ponesimod (Ponvory) for relapsing remitting multiple sclerosis rejected by NICE
13 Oct 2021 - 00:00
The MS Trust is very disappointed that NICE does not recommend ponesimod (Ponvory) as an NHS treatment in England and Wales.
Multiple sclerosis and disease modifying drugs, what are my options?
28 Sep 2021 - 00:00
We interview Dr Sharmilee Gnanapavan, a Consultant Neurologist at Bart's Health to get some answers on what's new in the world of disease modifying drugs and multiple sclerosis.
New report highlights barriers to accessing Sativex across the UK
18 Aug 2021 - 00:00
Fewer than 13% of people in England eligible for Sativex can access it, according to a new report published today. People living in Wales, Scotland and Northern Ireland also face difficulties.
Move it for MS Nick's story
7 Oct 2021 - 00:00
Nick, was diagnosed with relapsing remitting Multiple Sclerosis at the start of the first lockdown. In this story we talk to him about how he coped with his diagnosis and how running helps him with his MS.
David's diary - Inclusion and diversity, where are we now?
6 Oct 2021 - 00:00
Just over a year ago we published a diary entry about Inclusivity and Diversity at the MS Trust. In this piece we take a look at what's changed since then and what we still need to do.
Flu season 2021
4 Oct 2021 - 00:00
This year is likely to involve a bigger flu vaccination programme in the UK, including for people with multiple sclerosis (MS), due to the circulation of Covid-19 at the same time. Here we discuss who's eligible for a flu jab on the NHS and how to get one.
Sign up for updates from us
Keep up-to-date with the latest MS news, explore new research, read the stories of people living with MS, find out practical tips from MS experts, and discover exciting fundraising opportunities.